A forum for researchers, students and applicants in the field of cyclodextrin technology
Marinus Pharmaceuticals, a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders,
After years of slow growth, Amgen’s Kyprolis finally looks poised to break the blockbuster barrier in 2019, and new data
A new clinical trial with a rather innovative use of cyclodextrins is about to start shortly, although the recruitment has
Ligand Pharmaceuticals Incorporated announced positive top line results from a Phase 1 clinical trial of its internal Captisol-enabled (CE) Iohexol
Aldeyra Therapeutics Announced Results from the SOLACE Trial in Noninfectious Anterior Uveitis. The main points are: Statistical Significance Not Achieved
A recently posted phase 2 clinical trial (not yet recruiting) aims to evaluate the effect of ADV6209, a new oral
Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today
Ligand Pharmaceuticals Incorporated announced completion of enrollment of the Company’s Phase 1 clinical trial of its internal Captisol-enabled (CE) Iohexol
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of
This study is designed to compare the bioavailability of the test Product (CE-Iohexol Injection) and the reference product Iohexol Injection
